Positive News SentimentPositive News OKYO Pharma Stock Price, News & Analysis (NASDAQ:OKYO) $1.66 +0.04 (+2.46%) (As of 12/1/2023 ET) Add Compare Share Share Today's Range$1.63▼$1.7350-Day Range$1.57▼$2.7552-Week Range$0.92▼$7.00Volume4,798 shsAverage Volume26,443 shsMarket Capitalization$48.00 millionP/E RatioN/ADividend YieldN/APrice Target$4.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media OKYO Pharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside140.2% Upside$4.00 Price TargetShort InterestHealthy0.46% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$25,005 Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.17 out of 5 starsMedical Sector432nd out of 954 stocksBiotechnology Industry11th out of 24 stocks 3.5 Analyst's Opinion Consensus RatingOKYO Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.00, OKYO Pharma has a forecasted upside of 140.2% from its current price of $1.67.Amount of Analyst CoverageOKYO Pharma has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.46% of the float of OKYO Pharma has been sold short.Short Interest Ratio / Days to CoverOKYO Pharma has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month Previous Next 0.0 Dividend Strength Dividend YieldOKYO Pharma does not currently pay a dividend.Dividend GrowthOKYO Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for OKYO. Previous Next 2.7 News and Social Media Coverage News SentimentOKYO Pharma has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for OKYO Pharma this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for OKYO on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, OKYO Pharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $25,005.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders40.46% of the stock of OKYO Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 0.05% of the stock of OKYO Pharma is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for OKYO Pharma are expected to remain at ($0.40) per share in the coming year. Previous Next See Top Rated MarketRank™ Stocks Here About OKYO Pharma Stock (NASDAQ:OKYO)OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.Read More OKYO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OKYO Stock News HeadlinesOctober 31, 2023 | msn.comOKYO Pharma announces $5.84M cash raise and payables reductionOctober 9, 2023 | finance.yahoo.comOKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (“NCP”)December 2, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.September 15, 2023 | finance.yahoo.comOKYO Pharma Announces Closing of $4.0 Million Registered Direct Offering of Ordinary SharesSeptember 13, 2023 | proactiveinvestors.comOKYO Pharma announces share offeringSeptember 13, 2023 | finance.yahoo.comOKYO Pharma Announces Public Offering of Ordinary SharesSeptember 8, 2023 | proactiveinvestors.comOKYO Pharma completes enrollment in Phase 2 clinical trial to treat dry eye diseaseSeptember 8, 2023 | barrons.comOkyo Pharma Ltd.December 2, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.August 30, 2023 | benzinga.comThinking about buying stock in T2 Biosystems, OKYO Pharma, Mullen Automotive, Digital Media Solutions, or Orbital Infrastructure Group?August 30, 2023 | proactiveinvestors.comOKYO Pharma dry eye disease trial reaches enrollment milestone; topline data expected by year-endAugust 29, 2023 | finance.yahoo.comOKYO Pharma Limited Regains Compliance with Nasdaq Listing Minimum Market Value RuleAugust 15, 2023 | finance.yahoo.comOKYO Pharma Limited Reports Annual Results for the Twelve Months Ended March 31, 2023August 1, 2023 | investorplace.comWhy Is OKYO Pharma (OKYO) Stock Down 19% Today?July 31, 2023 | msn.comOKYO Pharma rebounds on withdrawal of equity offeringJuly 31, 2023 | finance.yahoo.comOKYO Pharma Limited Announces Withdrawal of Public OfferingJuly 28, 2023 | marketwatch.comOKYO Pharma Shares Rise 19% After Trial Agreement With Tufts Medical CenterJuly 28, 2023 | finance.yahoo.comOKYO Pharma Plans to Initiate Phase 2 Trial of OK-101 in Neuropathic Corneal Pain (“NCP”) Following Announcement of Clinical Trial Agreement with Tufts Medical CenterJuly 27, 2023 | finance.yahoo.comOKYO Pharma Announces Appointment of William A. Clementi as Chief Operating OfficerJune 6, 2023 | finance.yahoo.comOKYO Pharma Announces Randomized Segment Now Underway in Phase 2 Clinical Trial of Topical Ocular OK-101 for Dry Eye DiseaseMay 12, 2023 | benzinga.comPhase 2 Trials Begin For Promising New Dry Eye Disease Treatment From OKYO PharmaMay 5, 2023 | nz.finance.yahoo.comOKYO Pharma Limited (OKYO) stock price, news, quote & history – Yahoo FinanceMay 3, 2023 | finance.yahoo.comUveitis Market to Witness Upsurge in Growth at a CAGR of 4.8% During the Study Period (2019-2032), Assesses DelveInsightMay 3, 2023 | proactiveinvestors.comOKYO Pharma to address key conference with data on dry eye drugMay 3, 2023 | finance.yahoo.comOKYO Pharma Announces Presentations at the American Society of Cataract and Refractive Surgery (ASCRS 2023) in San Diego, CA, May 5-8, 2023April 25, 2023 | proactiveinvestors.comOKYO Pharma ready to kick off dry eye trial in the USApril 25, 2023 | finance.yahoo.comOKYO Pharma Announces Activation of First Clinical Trial Site in the U.S. for the Phase 2 Trial Evaluating OK-101 for the Treatment of Dry Eye DiseaseSee More Headlines Receive OKYO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OKYO Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today12/02/2023Next Earnings (Estimated)12/28/2023Fiscal Year End3/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:OKYO CUSIPN/A CIK1849296 Webwww.okyopharma.com Phone44-20-7495-2379FaxN/AEmployees8Year FoundedN/APrice Target and Rating Average Stock Price Target$4.00 High Stock Price Target$4.00 Low Stock Price Target$4.00 Potential Upside/Downside+140.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.72 Quick Ratio0.72 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.08) per share Price / Book-20.81Miscellaneous Outstanding Shares28,830,000Free Float17,167,000Market Cap$48.00 million OptionableNot Optionable Beta0.05 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. Gary S. Jacob Ph.D. (Age 76)CEO & Executive Director Comp: $650kMr. Michael Paul Beck (Age 66)Founder Ms. Keeren Shah (Age 46)Chief Financial Officer Dr. William A. Clementi Ph.D.Pharm.D., Chief Operating OfficerDr. Rajkumar Patil Ph.D. (Age 64)Chief Scientific Officer Key CompetitorsSAB BiotherapeuticsNASDAQ:SABSPrecision BioSciencesNASDAQ:DTILDyadic InternationalNASDAQ:DYAIInstil BioNASDAQ:TILAligos TherapeuticsNASDAQ:ALGSView All CompetitorsInsiders & InstitutionsBarclays PLCBought 25,000 shares on 11/7/2023Ownership: 0.087%John P BrancaccioBought 16,670 shares on 9/15/2023Total: $25,005.00 ($1.50/share)View All Insider TransactionsView All Institutional Transactions OKYO Stock Analysis - Frequently Asked Questions Should I buy or sell OKYO Pharma stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for OKYO Pharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" OKYO shares. View OKYO analyst ratings or view top-rated stocks. What is OKYO Pharma's stock price target for 2024? 1 brokers have issued 1-year target prices for OKYO Pharma's stock. Their OKYO share price targets range from $4.00 to $4.00. On average, they predict the company's stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 140.2% from the stock's current price. View analysts price targets for OKYO or view top-rated stocks among Wall Street analysts. How have OKYO shares performed in 2023? OKYO Pharma's stock was trading at $1.91 on January 1st, 2023. Since then, OKYO shares have decreased by 12.8% and is now trading at $1.6650. View the best growth stocks for 2023 here. When is OKYO Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, December 28th 2023. View our OKYO earnings forecast. When did OKYO Pharma IPO? (OKYO) raised $2 million in an initial public offering on Tuesday, May 17th 2022. The company issued 625,000 shares at a price of $4.00 per share. Who are OKYO Pharma's major shareholders? OKYO Pharma's stock is owned by many different retail and institutional investors. Top institutional investors include Barclays PLC (0.09%). View institutional ownership trends. How do I buy shares of OKYO Pharma? Shares of OKYO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:OKYO) was last updated on 12/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OKYO Pharma Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.